Breaking WORLD PHARMA NEWS

Child cancer groups call for concerted action

It’s one of the cruelest ironies in health and medicine. Pediatric sarcomas are some of the rarest yet most aggressive forms of childhood cancer, and some of the hardest to cure. Whereas many adult cancers are now treatable with new therapeutic strategies, such as immunotherapies, pediatric sarcomas have not seen nearly as many advances. Survival rates have remained largely unchanged for decades.

Read more …

Experimental study points to systemic sclerosis treatment

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.

Read more …

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumours may influence how effectively a promising new generation of medicines can remove them, a study suggests.

Researchers found that PROTAC (Proteolysis Targeting Chimeras) drugs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer cells continually produce in large amounts.

Read more …

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Sanofi and Cheplapharm, a European leader in well-established medicines, announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.

Read more …

Hidden immune cells in the lung could lead to better flu vaccines

Influenza continues to cause major illness each year in the United States, leading to more than 35,000 deaths annually. Children, older adults, pregnant individuals, people with weakened immune systems, and those with chronic conditions such as heart disease, metabolic disorders, and cancer are especially vulnerable.

Vaccination remains the most effective way to prevent flu infection, but current vaccines do not always stop the virus from taking hold in the respiratory tract.

Read more …

Novel drug shows promise in an early phase trial in heart failure

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.

Despite several guideline-directed medical therapies for heart failure, many patients continue to experience considerable disease burden.

Read more …

Cholesterol-lowering medication reduces heart attack and stroke risk in older people by 30%

A world-first clinical trial conducted by Monash University researchers has shown that cholesterol-lowering medication can reduce heart attack and stroke in people aged over 70 years.

Statins are commonly prescribed to manage high cholesterol in people up to 75 years, and are known to reduce the risk of heart attack and stroke.

Read more …

Scientists decode gene circuits of human immunity, fueling new era of disease research

Scientists from Gladstone Institutes, UC San Francisco, and Stanford University, in collaboration with Biohub, have unveiled a massive, high-resolution functional map of human immune cells that promises to transform our understanding of how genetics control health and disease.

Published in the journal Cell, the study represents a landmark achievement in immunology and genomics.

Read more …

FDA approves first in class targeted therapy for metastatic pancreatic cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer - delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

This action demonstrates the agency’s commitment to moving with urgency, reducing unnecessary delays and advancing innovative treatments that can make a meaningful difference in the lives of American patients and their families.

Read more …

Rethinking oral cancer treatment: A review of next-generation drug delivery systems

Delivering drugs directly to oral tumor sites remains challenging. A recent review involving researchers from Hasanuddin University examines barriers to local drug delivery and analyses strategies for targeting oral cancer lesions. Saliva, chewing, tongue movement, and individual tumor characteristics can affect how long a medicine remains at the treatment site and how consistently it is released.

Read more …